Improved Hematologic Outcomes in HIV1-Exposed Infants Receiving Nevirapine Compared With Zidovudine for Postnatal Prophylaxis in a High Resource Setting.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
10
2
2022
medline:
15
4
2022
entrez:
9
2
2022
Statut:
ppublish
Résumé
In the ANRS French Perinatal Cohort, we compared outcomes in 830 HIV1-exposed infants who received either nevirapine (NVP) or zidovudine postnatal prophylaxis. At 1 month, anemia grade ≥2 was less frequent on NVP than zidovudine (2.9% vs. 8.0%; P = 0.01), favoring the use of NVP as a first choice prophylaxis in infants at low risk of HIV acquisition.
Identifiants
pubmed: 35135997
doi: 10.1097/INF.0000000000003478
pii: 00006454-202205000-00014
doi:
Substances chimiques
Anti-HIV Agents
0
Zidovudine
4B9XT59T7S
Nevirapine
99DK7FVK1H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
420-423Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
P.F. received research grants (to his institution) from the French National Agency for AIDS Research (ANRS) and honoraria and travel grants from ViiV Healthcare, Bristol-Myers Squibb, Janssen Cilag, Gilead Sciences, and MSD France for participation in advisory boards, educational programs and conferences. The other authors have no conflicts of interest to disclose.
Références
Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al.; Enquête Périnatale Française Study Group. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS. 2003;17:2053–2061.
Nguyen TTT, Kobbe R, Schulze-Sturm U, et al. Reducing hematologic toxicity with short course postexposure prophylaxis with zidovudine for HIV-1 exposed infants with low transmission risk. Pediatr Infect Dis J. 2019;38:727–730.
Morlat P. 2015. Prise en charge médicale des personnes vivant avec le VIH recommandations du groupe d’experts. www.sante.gouv.fr
Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal HIV Transmission from women with effective antiretroviral therapy starting before conception. CID. 2015;61:1715–1725
Pacheco SE, McIntosh K, Lu M, et al.; Women and Infants Transmission Study. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis. 2006;194:1089–1097.
Baroncelli S, Pinnetti C, Genovese O, et al. Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine. J Med Virol. 2011;83:551–556.
Fowler MG, Coovadia H, Herron CM, et al.; HPTN 046 Protocol Team. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2014;65:366–374.
European Pregnancy and Pediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Severe haematologic toxicity in rare in high-risk HIV-exposed infants receiving combination neonatal prophylaxis. HIV Med. 2019; 20:291–307.
de Waal R, Kroon SM, Holgate SL, et al. Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations. Pediatr Infect Dis J. 2014;33:1231–1233.
Delaugerre C, Chaix ML, Blanche S, et al.; ANRS French Perinatal Cohort. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology. 2009;6:85.